Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($1.08), $0.06 worse than the analyst estimate of ($1.02). Revenue for the quarter came in at $31 million versus the consensus estimate of $29.03 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.